Current Research Studies

Clinical Trial: Tangelo

Clinical Trial: Tangelo

RocheThe Tangleo clinical trial, sponsored by Hoffman La Roche is now open.  This is a study of the safety and tolerability of RO7248824 in children with Angelman syndrome. 

Participant Requirements

Below is a preliminary list of inclusion criteria: 

Inclusion Criteria

  • Diagnosis of Angelman syndrome
  • Between 1 and 12 years old
  • Stable medical status for 4 weeks prior to screening visit
  • Ability to tolerate blood draws
  • Able to undergo LP and IT injection, under sedation or anesthesia 3 times during an 8-week period

See the full list of Eligibility Criteria on the clinical trials website


Locations & Contacts

Currently, the study is taking place in multiple locations world-wide.

UCLA Neuropsychiatric Institute 
Los Angeles, CA
(323) 361-2471

Rady Children’s Hospital – San Diego
San Diego, CA
Lynne Bird, MD –

Rush University Medical Center
Chicago, IL
Kathryn Kudlacz –

University of North Carolina
Carrboro, NC
Hannah Riehl –

Baylor College of Medicine/ Texas Children’s Hospital
Houston, TX
Beverly Feldman –


Ospedale Pediatrico Bambino Gesù; Dip. Neuroscienze e Neuroriabilitazione 
Roma, Lazio, Italy

Erasmus MC / location Sophia Kinderziekenhuis  
Rotterdam, Netherlands

Corporacio Sanitaria Parc Tauli  
Sabadell, Barcelona, Spain

Hospital Universitario Virgen del Rocío  
Sevilla, Spain

Hospital Sant Joan De Deu
Esplugues De Llobregas, Barcelona, Spain


More Information and Screening Enrollment

Find more information on the Roche website. 

More details on

Questions about this study and enrollment interest can be directed to: 
888-662-6728 (U.S. and Canada) or 

Reference Study ID Number: BP41674


The Angelman Syndrome Foundation does not endorse any clinical trial or study, but provides information to the AS community for its own consideration.